|
|
 Previous Article | Table of Contents | Next Article 
Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice
Thomas H. Bugge,
Keith W. Kombrinck,
Qing Xiao,
Kenn Holmbäck,
Cynthia C. Daugherty,
Dave P. Witte, and
Jay L. Degen
From the Divisions of Developmental Biology and Pathology, Children's Hospital Research Foundation, Cincinnati, OH.
Plasminogen activation has been proposed to play a critical role in cancer invasion and metastasis. The effects of complete ablation of plasminogen activation in cancer was studied by inoculation of a metastatic Lewis lung carcinoma expressing high levels of plasminogen activator into plasminogen-deficient (Plg-/-) mice and matched control mice. Primary tumors developed in all mice with no difference in the rate of appearance between Plg-/- and control mice. However, the primary tumors in Plg-/- mice were smaller and less hemorrhagic and displayed reduced skin ulceration. In addition, dissemination of the tumor to regional lymph nodes was delayed in Plg-/- mice. Surprisingly, no quantitative differences were observed in lung metastasis between Plg-/- and control mice. In addition, Plg deficiency was compatible with metastasis of the primary tumor to a variety of other organs. Nevertheless, Plg-/- mice displayed a moderately increased survival after primary tumor resection. These findings suggest that plasmin-mediated proteolysis contributes to the morbidity and mortality of Lewis lung carcinoma in mice, but sufficient proteolytic activity is generated in Plg-/- mice for efficient tumor development and metastasis.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4522-4531
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. Mitchell, N. Baik, F. J. Castellino, and L. A. Miles
Plasminogen inhibits TNF{alpha}-induced apoptosis in monocytes
Blood,
June 1, 2006;
107(11):
4383 - 4390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Rao, C. Gondi, C. Chetty, S. Chittivelu, P. A. Joseph, and S. S. Lakka
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells
Mol. Cancer Ther.,
September 1, 2005;
4(9):
1399 - 1408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Grum-Schwensen, J. Klingelhofer, C. H. Berg, C. El-Naaman, M. Grigorian, E. Lukanidin, and N. Ambartsumian
Suppression of Tumor Development and Metastasis Formation in Mice Lacking the S100A4(mts1) Gene
Cancer Res.,
May 1, 2005;
65(9):
3772 - 3780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Navab, J. M. Gonzalez-Santos, M. R. Johnston, J. Liu, P. Brodt, M.-S. Tsao, and J. Hu
Expression of Chicken Ovalbumin Upstream Promoter-Transcription Factor II Enhances Invasiveness of Human Lung Carcinoma Cells
Cancer Res.,
August 1, 2004;
64(15):
5097 - 5105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Noel, C Maillard, N Rocks, M Jost, V Chabottaux, N E Sounni, E Maquoi, D Cataldo, and J M Foidart
Membrane associated proteases and their inhibitors in tumour angiogenesis
J. Clin. Pathol.,
June 1, 2004;
57(6):
577 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Palumbo, K. E. Talmage, H. Liu, C. M. La Jeunesse, D. P. Witte, and J. L. Degen
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency
Blood,
October 15, 2003;
102(8):
2819 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. McColl, M. E. Baldwin, S. Roufail, C. Freeman, R. L. Moritz, R. J. Simpson, K. Alitalo, S. A. Stacker, and M. G. Achen
Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D
J. Exp. Med.,
September 15, 2003;
198(6):
863 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Currier, G. Sabla, S. Locaputo, H. Melin-Aldana, J. L. Degen, and J. A. Bezerra
Plasminogen directs the pleiotropic effects of uPA in liver injury and repair
Am J Physiol Gastrointest Liver Physiol,
March 1, 2003;
284(3):
G508 - G515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu, H. Aaronson, D. J. Mitola, S. H. Leppla, and T. H. Bugge
Potent antitumor activity of a urokinase-activated engineered anthrax toxin
PNAS,
January 21, 2003;
100(2):
657 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Han, J. Leng, D. Bian, C. Mahanivong, K. A. Carpenter, Z. K. Pan, J. Han, and S. Huang
Rac1-MKK3-p38-MAPKAPK2 Pathway Promotes Urokinase Plasminogen Activator mRNA Stability in Invasive Breast Cancer Cells
J. Biol. Chem.,
December 6, 2002;
277(50):
48379 - 48385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Palumbo, J. M. Potter, L. S. Kaplan, K. Talmage, D. G. Jackson, and J. L. Degen
Spontaneous Hematogenous and Lymphatic Metastasis, but not Primary Tumor Growth or Angiogenesis, Is Diminished in Fibrinogen-deficient Mice
Cancer Res.,
December 1, 2002;
62(23):
6966 - 6972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Hotary, I. Yana, F. Sabeh, X.-Y. Li, K. Holmbeck, H. Birkedal-Hansen, E. D. Allen, N. Hiraoka, and S. J. Weiss
Matrix Metalloproteinases (MMPs) Regulate Fibrin-invasive Activity via MT1-MMP-dependent and -independent Processes
J. Exp. Med.,
January 28, 2002;
195(3):
295 - 308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vakili, L. Standker, M. Detheux, G. Vassart, W.-G. Forssmann, and M. Parmentier
Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9-74] Processed Variant
J. Immunol.,
September 15, 2001;
167(6):
3406 - 3413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mohanam, S. L. Jasti, S. R. Kondraganti, N. Chandrasekar, Y. Kin, G. N. Fuller, S. S. Lakka, A. P. Kyritsis, D. H. Dinh, W. C. Olivero, et al.
Stable Transfection of Urokinase-Type Plasminogen Activator Antisense Construct Modulates Invasion of Human Glioblastoma Cells
Clin. Cancer Res.,
August 1, 2001;
7(8):
2519 - 2526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bajou, V. Masson, R. D. Gerard, P. M. Schmitt, V. Albert, M. Praus, L. R. Lund, T. L. Frandsen, N. Brunner, K. Dano, et al.
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies
J. Cell Biol.,
February 20, 2001;
152(4):
777 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Palumbo, K. W. Kombrinck, A. F. Drew, T. S. Grimes, J. H. Kiser, J. L. Degen, and T. H. Bugge
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells
Blood,
November 15, 2000;
96(10):
3302 - 3309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Gutierrez, A. Schulman, T. Brito-Robinson, F. Noria, V. A. Ploplis, and F. J. Castellino
Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor-1
Cancer Res.,
October 1, 2000;
60(20):
5839 - 5847.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. M. Swaisgood, E. L. French, C. Noga, R. H. Simon, and V. A. Ploplis
The Development of Bleomycin-Induced Pulmonary Fibrosis in Mice Deficient for Components of the Fibrinolytic System
Am. J. Pathol.,
July 1, 2000;
157(1):
177 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Carriero, S. D. Vecchio, M. Capozzoli, P. Franco, L. Fontana, A. Zannetti, G. Botti, G. D'Aiuto, M. Salvatore, and M. P. Stoppelli
Urokinase Receptor Interacts with {{alpha}}v{{beta}}5 Vitronectin Receptor, Promoting Urokinase-dependent Cell Migration in Breast Cancer
Cancer Res.,
October 1, 1999;
59(20):
5307 - 5314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.F. Drew, A.H. Kaufman, K.W. Kombrinck, M.J.S. Danton, C.C. Daugherty, J.L. Degen, and T.H. Bugge
Ligneous Conjunctivitis in Plasminogen-Deficient Mice
Blood,
March 1, 1998;
91(5):
1616 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu, T. H. Bugge, and S. H. Leppla
Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin
J. Biol. Chem.,
May 18, 2001;
276(21):
17976 - 17984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
